Wire · opportunities
FDA Approves Reduced Monitoring Time for First 2 Doses of Tarlatamab in ES-SCLC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 September 2026 · Fusion42 review
The FDA has reduced the required post-infusion monitoring time for the first two doses of tarlatamab in patients with extensive-stage small cell lung cancer from 22-24 hours to 6-8 hours, easing treatment logistics. This update follows the drug's full FDA approval based on confirmatory phase 3 trial data showing significant survival benefits.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now have a clearer pathway to offer tarlatamab with less intensive monitoring in the US, reducing treatment burden and enabling more convenient administration closer to patients’ homes. This change opens practical room for patient access and could shift care delivery models for ES-SCLC.
◆ Coverage
1 source · 14 Sep 2026
◆ Related on Wire
◆ Topics